TY - T1的真实长期omalizumab特产apy in children with severe allergic asthma JF - European Respiratory Journal JO - Eur Respir J SP - 856 LP - 859 DO - 10.1183/09031936.00008115 VL - 46 IS - 3 AU - Deschildre, Antoine AU - Marguet, Christophe AU - Langlois, Carole AU - Pin, Isabelle AU - Rittié, Jean-Luc AU - Derelle, Jocelyne AU - Abou Taam, Rola AU - Fayon, Michael AU - Brouard, Jacques AU - Dubus, Jean Christophe AU - Siret, Daniel AU - Weiss, Laurence AU - Pouessel, Guillaume AU - Beghin, Laurent AU - Just, Jocelyne Y1 - 2015/09/01 UR - //www.qdcxjkg.com/content/46/3/856.abstract N2 - We previously reported the French real-life experience of 1 year of add-on treatment with omalizumab in 101 severe allergic asthmatic children (6–18 years), 92 of whom were still receiving the treatment at the end of the first year [1]. The study provided complementary data to the previous randomised trials [2–6]. We showed a marked drop of 72% in the mean rate of severe exacerbations (from 4.4 per patient during the preceding year to 1.25 during the year of treatment) and of 88.5% for hospitalisations (44% of the patients during the preceding year to 6.7% during the year of treatment); a large improvement in asthma control (from 0% at initiation to 67% of well-controlled patients after 1 year); a decrease of 30% of the mean inhaled corticosteroid (ICS) dose (from 703 at initiation to 488 µg fluticasone equivalent per day after 1 year); and a forced expiratory volume in 1 s (FEV1) increase, from a mean of 88% to 92.1% of the predicted value. Treatment was discontinued in six patients due to serious adverse events attributed to omalizumab by the practitioner. Here we report the outcome of this cohort after 2 years of omalizumab treatment.Beneficial effects at 2 years of omalizumab on severe exacerbations and control in severe allergic asthmatic children http://ow.ly/LGgnwWe are grateful to Céline Clairet (Centre d'Investigations Cliniques Pédiatriques, Lille University Hospital, Lille, France) for data collection and management. ER -